Metvix (Methyl Aminolevulinate)

Methyl aminolevulinate is converted inside skin cells to protoporphyrin IX, a photosensitizer. When the treated area is exposed to red light, the protoporphyrin IX generates reactive oxygen species that selectively destroy abnormal keratinocytes while sparing normal tissue.

The prescribed amount of Metvix is determined by the treating physician based on the extent of the lesion field and the illumination protocol. The prescriber decides the quantity of cream to apply and the timing of light exposure.

The safety of Metvix in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To request Metvix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metvix offers a field‑directed photodynamic approach, allowing treatment of multiple lesions simultaneously, whereas topical agents such as 5‑fluorouracil or imiquimod act locally and may require longer treatment periods. Cryotherapy treats individual lesions but does not address subclinical disease. Choice depends on lesion extent, patient preference and clinical judgment.

Store Metvix at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from light and moisture, and avoid freezing. Do not refrigerate unless specifically instructed by the manufacturer.

Metvix is applied topically to the affected skin area, usually in a thin, uniform layer. After a defined incubation period (typically 3 hours), the area is illuminated with red light of approximately 630 nm wavelength. The procedure is performed by a qualified healthcare professional in a clinical setting.

Serious risks include severe photosensitivity reactions that may extend beyond the treated field, allergic dermatitis, secondary skin infection, persistent scarring or hypopigmentation, and rare systemic effects such as hemolysis in susceptible individuals. Prompt medical attention is required if any of these occur.

Metvix should not be used in individuals with known hypersensitivity to methyl aminolevulinate, other porphyrins, or any component of the formulation. It is also contraindicated in patients who have received other photodynamic therapy agents on the same area or who cannot avoid sunlight exposure during the post‑treatment period.